Adipokines as Uremic Toxins

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 81-85

  Teta, Daniel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

ADIPOSE TISSUE; ARTICLE; BLOOD; DRUG TOXICITY; HUMAN; INFLAMMATION; METABOLISM; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; UREMIA;

ADIPOKINES; ADIPONECTIN; ADIPOSE TISSUE; DRUG TOXICITY; HUMANS; INFLAMMATION; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; OXIDATIVE STRESS; RESISTIN; SIGNAL TRANSDUCTION; UREMIA;

EID: 84855185250     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.029     Document Type: Article

References (22)

1. Axelsson J., Stenvinkel P. Role of fat mass and adipokines in chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:25-31.
2. Axelsson J. Obesity in chronic kidney disease: good or bad?. Blood Purif 2008, 26:23-29.
3. Axelsson J., Astrom G., Sjolin E., et al. Uremic sera stimulate lipolysis in human adipocytes: role of perilipin. Nephrol Dial Transplant 2011, 26:2485-2491.
4. Vanholder R., De Smet R., Glorieux G., et al. European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63:1934-1943.
5. Vanholder R., Van Laecke S., Glorieux G. What is new in uremic toxicity?. Pediatr Nephrol 2008, 23:1211-1221.
6. Stenvinkel P. Leptin-a new hormone of definite interest for the nephrologists. Nephrol Dial Transplant 2002, 13:1099-1101.
7. Teta D., Maillard M., Halabi G., Burnier M. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int Suppl 2008, 108:S112-S118.
8. Odamaki M., Furuya R., Yoneyama, et al. Association of the serum leptin concentration with weight loss in chronic hemodialysis patient. Am J Kidney Dis 1999, 33:361-368.
9. Bossola M., Muscaritoli M., Tazza L., et al. Variables associated with reduced dietary intake in hemodialysis patients. J Ren Nutr 2005, 15:244-252.
10. Ottonello L., Gnerre P., Bertolotto M., et al. Leptin as a uremic toxin interferes with neutrophil chemotaxis. J Am Soc Nephrol 2004, 15:2366-2372.
11. Wiesholzer M., Harm F., Hauser A.C., Pribasnig A., Balcke P. Inappropriately high plasma leptin levels in obese haemodialysis patients can be reduced by high flux haemodialysis and haemodiafiltration. Clin Sci (Lond) 1998, 94:431-435.
12. Kim S., Oh K.H., Chin H.J., et al. Effective removal of leptin via hemodiafiltration with on-line endogenous reinfusion therapy. Clin Nephrol 2009, 72:442-448.
13. Adamczak M., Chudek J., Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial 2009, 22:391-395.
14. Park G.H., Gil H.W., Yang J.O., Lee E.Y., Hong S.Y. Total and high molecular weight adiponectin concentrations in plasma of patients with end-stage renal disease before and after peritoneal dialysis. Nephrology (Carlton) 2008, 13:181-185.
15. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
16. Yu Z.Z., Ni Z.H., Gu L.Y., et al. Adiponectin is related to carotid artery plaque and a predictor of cardiovascular outcome in a cohort of non-diabetic peritoneal dialysis patients. Blood Purif 2008, 26:386-393.
17. Drechsler C., Krane V., Winkler K. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009, 76:567-575.
18. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 2011, 21:82-86.
19. Cohen G., Horl W.H. Resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin. Semin Dial 2009, 22:373-377.
20. Cohen G., Ilic D., Raupachova J., Hörl W.H. Resistin inhibits essential functions of polymorphonuclear leucocytes. JImmunol 2008, 181:3761-3768.
21. Yilmaz M.I., Saglam M., Carrero J.J., et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008, 23:959-965.
22. Yamamoto T., Qureshi A.R., Anderstam B., et al. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant 2010, 25:4017-4023.